Allakos Inc (Allakos) is a clinical-stage biotechnology company that develops antibodies that target immunomodulatory receptors present on immune effector cells. The company investigates the therapeutic areas of eosinophilic gastrointestinal diseases, chronic inflammatory diseases with continuing gastrointestinal symptoms along with an increase in the count of mast cells in the body. Its product offerings include AK002, an antibody that targets Siglec-8, an inhibitory receptor for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic and mastocytosis. The company is discovering AK007 to treat immuno-oncology disease. It partners with universities ad pharmaceutical companies. Allakos is headquartered in Redwood City, California, the US.
Allakos Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
AK002: |
Allergic, Inflammatory and Proliferative Diseases |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Plans/Strategy | In November, the company announced its plans to raise up to US$250 million in public offering of common stock. |
2022 | Others | In May, the company announced the filing for offering of up to US$250 million shares of common stock. |
2021 | Others | In November, the company initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis. |
Competitor Comparison
Key Parameters | Allakos Inc | F. Hoffmann-La Roche Ltd | Pfizer Inc | AbbVie Inc | Sanofi |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United States of America | United States of America | France |
City | San Carlos | Basel | New York | North Chicago | Paris |
State/Province | California | - | New York | Illinois | Ile-de-France |
No. of Employees | 131 | 103,605 | 88,000 | 50,000 | 87,994 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Daniel Janney | Chairman | Executive Board | 2017 | 57 |
Robert Alexander | Chief Executive Officer; Director | Executive Board | 2017 | 53 |
Baird Radford | Chief Financial Officer | Senior Management | 2021 | 53 |
Craig Paterson | Chief Medical Officer | Senior Management | 2021 | 58 |
Adam Tomasi | President | Senior Management | 2019 | 53 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer